Request Demo
Last update 22 Oct 2026
Sacituzumab tirumotecan
Last update 22 Oct 2026
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264 + [7] |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 inhibitors(Tumor-associated calcium signal transducer 2 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (22 Nov 2024), |
RegulationBreakthrough Therapy (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China) |
Login to view timeline
Structure/Sequence
Boost your research with our ADC technology data.
login
or
Sequence Code 27958L
Source: *****
Sequence Code 319372635H
Source: *****
Related
178
Clinical Trials associated with Sacituzumab tirumotecanNCT07750353
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic carcinoma who have a history of platinum-based combination chemotherapy.
Start Date01 Feb 2027 |
Sponsor / Collaborator |
ACTRN12626000937314
IMPACT - A phase 2 study of IMmunotherapy with Pembrolizumab and sACituzumab Tirumotecan in pMMR recurrent or advanced endometrial cancer
Start Date01 Feb 2027 |
Sponsor / Collaborator- |
JPRN-jRCT2031260381
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas (XANTHOS)
Start Date15 Jan 2027 |
Sponsor / Collaborator- |
100 Clinical Results associated with Sacituzumab tirumotecan
Login to view more data
100 Translational Medicine associated with Sacituzumab tirumotecan
Login to view more data
100 Patents (Medical) associated with Sacituzumab tirumotecan
Login to view more data
50
Literatures (Medical) associated with Sacituzumab tirumotecan01 Dec 2026·CURRENT TREATMENT OPTIONS IN ONCOLOGY
Antibody-Drug Conjugates in the Treatment of Esophageal Cancer
Review
Author: Zhao, Qi ; Zhu, Wenjing ; Chen, Wei ; Xu, Jian ; Wu, Dapeng
OPINION STATEMENT:
Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies with potent cytotoxic payloads, enabling selective tumor cell killing while minimizing off-target toxicity. In the management of advanced esophageal cancer, I advocate for the integration of ADCs as a therapeutic option following progression on first-line chemoimmunotherapy. For patients with human epidermal growth factor receptor 2 (HER2)-positive gastroesophageal junction adenocarcinoma, trastuzumab deruxtecan is my preferred choice based on its superior overall survival benefit and robust bystander killing effect, which also confers activity in HER2-low tumors. For HER2-negative gastroesophageal adenocarcinoma, trophoblast cell-surface antigen 2 represents a promising target given its high prevalence of moderate to strong expression in nearly 80% of cases, and sacituzumab tirumotecan is currently under phase III investigation in this setting. In esophageal squamous cell carcinoma, I recommend biomarker-guided selection among ADCs targeting B7-H3, given its overexpression in over 90% of cases. For Nectin-4-expressing tumors, enfortumab vedotin may be considered as a later-line alternative despite modest activity. Notably, the bispecific ADC targeting both epidermal growth factor receptor and human epidermal growth factor receptor 3, BL-B01D1, has demonstrated compelling efficacy in immunotherapy-refractory esophageal squamous cell carcinoma, and I consider it a breakthrough option in this subtype. For claudin-18.2-positive gastroesophageal junction adenocarcinoma, several ADCs including CMG901, IBI343, and tecotabart vedotin represent promising later-line choices. I emphasize that patient selection should be guided by validated predictive biomarkers, and treatment decisions must account for distinctive toxicity profiles, particularly interstitial lung disease with trastuzumab deruxtecan. Finally, I strongly support advancing ADCs into earlier lines of therapy and perioperative settings through well-designed clinical trials to further improve long-term outcomes in this aggressive malignancy.
01 Oct 2026·BREAST
Antibody–drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer
Review
Author: Freire, Pedro José Galvão ; Barrios, Carlos ; Prado, Caio Guilherme Souza ; Lustberg, Maryam ; Kahn, Adriana ; Leite, Caio Abner ; Bonadio, Renata Colombo ; Gouveia, Mariana Carvalho ; Zucchetti, Bruna Migliavacca ; Barroso-Sousa, Romualdo
Antibody-drug conjugates (ADCs) have redefined therapeutic paradigms in metastatic breast cancer, offering unprecedented efficacy across hormone receptor-positive/HER2-negative and triple-negative subtypes. Trastuzumab deruxtecan, sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan are expanding treatment options beyond traditional chemotherapy. As their clinical integration advances, optimizing the prevention and management of ADC-related toxicities, determining optimal sequencing strategies, and refining biomarker characterization have become central challenges. Ongoing research into ADC combinations, earlier-line use, and precision biomarker selection is expected to further reshape the therapeutic landscape and personalize care for patients with advanced breast cancer.
02 Sep 2026·Expert Review of Anticancer Therapy
From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China
Article
Author: Lin, Shen ; Huang, Xiaoting ; Weng, Xiuhua ; Xu, Xiongwei ; Wang, Xiangzhen ; Yang, Lijing ; Luo, Shaohong
BACKGROUND:
Robust pharmacoeconomic evidence regarding the long-term affordability of sacituzumab tirumotecan (sac-TMT) in treatment of metastatic triple-negative breast cancer (TNBC) remains lacking. We evaluated the cost-effectiveness of sac-TMT versus chemotherapy for previously treated metastatic TNBC from the perspective of Chinese payers.
RESEARCH DESIGN AND METHODS:
A partitioned survival model was developed using clinical efficacy and safety data from the OptiTROP-Breast01 trial. Key inputs included survival probability, incidence of adverse events, direct medical costs, and utility values. Total costs, quality adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) were calculated as main outputs. Sensitivity analyses tested parameter uncertainty.
RESULTS:
Sac-TMT provided an incremental survival benefit of 0.40 QALY compared to chemotherapy but incurred extra costs of $33,029.53. The corresponding ICER was $82,573.83/QALY, substantially exceeding the willingness-to-pay (WTP) thresholds of $40,343.68/QALY. Drivers of unaffordability were utility value of progressive disease, price of sac-TMT, and body weight. Probabilistic sensitivity analysis showed that the probability of sac-TMT being cost-effective was 0.68%, and price simulation manifested that a 77.5% price reduction for sac-TMT could make it economical.
CONCLUSION:
Sac-TMT is not cost-effective for metastatic TNBC compared to chemotherapy at current pricing. Significant price reductions are essential to justify its economic value in resource-constrained settings.
209
News (Medical) associated with Sacituzumab tirumotecan22 Oct 2026
iStock,
Dilok Klaisataporn
At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its Kelun-Biotech–partnered TROP2-directed antibody sac-TMT that VP of Chemistry Alan Northrup says gets the payload release “just right.”
Twelve years ago, Merck won FDA approval for the PD-1 inhibitor Keytruda, heralding a
new era
of cancer treatment—and opening the door to billions of dollars in revenue. Now, with immuno-oncology seemingly on the verge of its
next breakthrough
, Merck is looking to stake a new claim on the market—this time in the growing space of antibody-drug conjugates.
While the antibody-drug conjugate (ADC) market is crowded with candidates, Merck Vice President of Chemistry Alan Northrup believes the company’s Kelun-Biotech–partnered TROP2 ADC is “just right.”
ADCs, which marry the targeting properties of antibodies with the cancer-killing capabilities of cytotoxic drugs such as chemotherapy in hopes of effectively destroying tumor cells while sparing the healthy ones, “remain one of oncology’s most attractive modalities,” Truist Securities said in an Oct. 12 note to investors, “but a crowded pipeline raises the bar for differentiation.”
H.C. Wainwright agreed, writing in a Sept. 28 Deep Dive on the space that “the ADC boom could reshape oncology, defend Merck’s $30B+ [Keytruda] franchise, and reward drugs that overcome resistance or keep patients on therapy.” Sac-TMT, specifically, “could preserve Merck’s central role in frontline oncology beyond Keytruda’s December 2028 primary U.S. patent expiration,” the analysts continued. They added that replacing conventional chemotherapy with ADCs while retaining Keytruda in treatment regimens could address the same large opportunity pursued by PD-(L)1/VEGF bispecific antibodies, which Vision Lifesciences
projects
will be worth $30 billion by 2032.
Merck’s
pipeline
currently includes six ADCs, a company representative confirmed, including the B7-H3 directed ifinatamab deruxtecan (I-DXd), the Nectin-4-directed MK-3120 and the Daiichi Sankyo–partnered patritumab deruxtecan. The subject of most attention, however, is Merck and Kelun’s sacituzumab tirumotecan (sac-TMT), a TROP-2-targeted ADC in development for a range of indications, including bladder, breast, cervical and endometrial cancer.
The Goldilocks zone
TROP2-directed ADCs are fairly new to the market. The first such drug—Gilead Sciences’ Trodelvy—was greenlit by the FDA in April 2020 for patients with metastatic triple-negative breast cancer. Three years later, AstraZeneca and Daiichi Sankyo’s Datroway was approved for the same disease.
Northrup explained that most ADCs—including Trodelvy and Datroway—have a reversible payload linkage to the antibody, while sac-TMT has an irreversible linkage, which keeps the drug stable in the blood until it reaches the tumor.
“You’re trying to find that Goldilocks zone,” he told
BioSpace
. Some linker payloads are “too hot,” so the payload is released throughout the body, and some are “too cold,” meaning their release is slow once they hit the tumor. “[Sac-TMT] is right in that middle zone where it’s just right.”
This is key to successful treatment, Northrup explained, because when a payload is released early, it is free to circulate through the body, causing myriad issues, including anemia and neutropenia—a condition in which the body has an unusually low number of neutrophils, which attack bacteria and other invaders. Merck believes these adverse effects are due to free payload. On the other hand, if payload release is delayed too long, “you may have also hit a lot of the on-target tissues as well, where TROP2 is expressed in other parts of the body.”
The irreversible linker was part of what drew Merck to Kelun nearly four years ago when the New Jersey giant committed
upwards of $9.4 billion biobucks
in December 2022 to work with the China-based biotech on seven ADC candidates for cancer targets.
“When we first met with Kelun and started talking with them about their technology, I think we were really impressed by this bifunctional linker because it was really unique in the field,” Northrup said. Merck was watching the development of Datroway and Trodelvy, “and we saw this as something that would be very unique in the field and would get it just right.”
So, is the proof in the proverbial porridge? “I think the trials speak for themselves,” Northrup said.
Sac-TMT will be featured in three late-breaking sessions at the
2026 European Society for Medical Oncology (ESMO) Congress
, which begins Friday in Madrid.
Sac-TMT’s clinical program
One of Merck’s ESMO late-breakers will feature the
Phase 3 OptiTROP-Lung06 trial
in non-small cell lung cancer (NSCLC). In results that read out in July, sac-TMT plus Keytruda meaningfully improved progression-free survival (PFS) vs. the first-line standard of care (immunotherapy plus chemotherapy), meeting the trial’s primary endpoint. The result established another breakthrough, according to Leerink Partners at the time: The first direct proof-of-concept for an ADC that could replace standard of care platinum-based chemo for first-line NSCLC.
Lung cancer
Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Partners. The readout also represents the second late-stage win for the Merck and Kelun-Biotech asset, called sac-TMT.
July 15, 2026
·
2 min read
·
Michael Gibney
Read more
It was also the first Phase 3 trial of an ADC combined with a checkpoint inhibitor to meet its primary endpoint in first-line driver gene–negative and PD‑L1–negative non-squamous NSCLC, Kelun said in its July 14
press release
.
RBC analysts at the time called the trial success “another positive for Merck’s sac-TMT franchise” as it extends the sac-TMT/Keytruda combo from the PD-L1-positive population into the more challenging PD-L1-negative segment.
Meanwhile, in their Oct. 12 note, Truist analysts said that “Sac-TMT and [Datroway] establish key efficacy and safety reference points for next-wave ADCs, with TROP2 remaining the most clinically advanced target.”
In the same slot on Sunday, Kelun and Merck will discuss final overall survival (OS) data from the Phase 3 OptiTROP-Lung04 trial, which pitted sac-TMT against platinum chemotherapy in EGFR-mutated NSCLC after progression on a treatment that blocks the EGFR tyrosine kinase domain. The risk of disease progression or death was 51% lower for patients taking the ADC, which met the trial’s primary endpoint, Kelun
reported
in October 2025. OS was a key secondary endpoint of the trial.
And on Monday, sac-TMT’s
successful Phase 3 TroFuse-005 trial
in advanced endometrial cancer will be showcased in the Presidential Symposium. In May, the partners reported that TroFuse-005 hit its primary endpoint at an interim analysis, demonstrating significantly better OS and PFS compared to chemo in patients who had undergone prior treatment with platinum-based and anti-PD-1 therapies. The companies promised to provide more details at an upcoming medical congress, which was expected to be ESMO.
It hasn’t all been smooth sailing for Merck’s ADC pipeline, though. The pharma and partner Daiichi Sankyo
withdrew an application
for accelerated approval of I-DXd in extensive-stage small cell lung cancer after the FDA found that the companies’ data package did not meet the criteria.
“As a field, we can always continue to get better at delivering precisely to the tumor,” Northrup said when asked whether there is a limit to what ADCs can do. He provided two ways in which this can be done: more specific targeting and a more efficacious linker payload, “making sure that you can hold tight to the antibody and release where you want to in the tumor.
“I think Sac-TMT does that very well.”
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
Merck and Kelun-Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial cancer study, though the companies have yet to specify when they plan to approval.
May 19, 2026
·
2 min read
·
Tristan Manalac
Read more
Phase 3Clinical ResultADCDrug Approval
13 Oct 2026
INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational intismeran autogene plus KEYTRUDA
®
(pembrolizumab), demonstrating improvements in recurrence-free survival and distant metastasis-free survival versus KEYTRUDA alone in patients with completely resected stage IIB-IV melanoma in the adjuvant setting
Investigational sacituzumab tirumotecan (sac-TMT) data from TroFuse-005, the first and only Phase 3 trial of a TROP2-directed antibody-drug conjugate to improve overall survival and progression-free survival in certain patients with advanced or recurrent endometrial cancer, will be presented in a Presidential Symposium
KEYNOTE-C93 data to be presented in Presidential Symposium suggesting important role of first-line KEYTRUDA monotherapy for certain patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer
RAHWAY, N.J.--(BUSINESS WIRE)--
$MRK
#MRK
--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27. Additionally, more than 90 additional abstracts across more than 20 tumor types from the company’s pipeline and portfolio will be presented throughout the meeting.
“New data at ESMO, including three Presidential Symposia from three pivotal trials, reflect the strength and depth of Merck’s industry-leading oncology portfolio and pipeline,” said Dr. Marjorie Green, senior vice president and head of oncology global clinical development, Merck Research Laboratories. "We are proud to share Phase 3 data for the first time from intismeran and sac-TMT, alongside new research from our oncology portfolio, reflecting our commitment to advancing research across a range of cancer types."
Key data from Merck’s pipeline and portfolio to be presented:
First presentation of data from the pivotal Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940/mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, in combination with KEYTRUDA
®
(pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma, which will be featured in an ESMO Presidential Symposium (Presentation #LBA1, Proffered paper session: Presidential Symposium I).
1
First presentation of data from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate, for patients with advanced or recurrent endometrial cancer who have progressed after platinum-based chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, which will be featured in an ESMO Presidential Symposium (Presentation #LBA11, Proffered paper session: Presidential Symposium III).
2,3
First presentation of data from the Phase 3 KEYNOTE-C93 trial evaluating KEYTRUDA monotherapy as a first-line treatment for patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer who had not previously received systemic chemotherapy or who experienced recurrence after receiving prior adjuvant therapy, which will be featured in an ESMO Presidential Symposium (Presentation #LBA12, Proffered paper session: Presidential Symposium III).
3
Data from Phase 3 OptiTROP studies evaluating sac-TMT in non-small cell lung cancer (NSCLC), including results from the OptiTROP-Lung06 study (Presentation #LBA66) in first-line PD-L1-negative advanced non-squamous NSCLC and final overall survival data from the OptiTROP-Lung04 study (Presentation #LBA67) in epidermal growth factor receptor (EGFR)-mutated NSCLC following progression on EGFR tyrosine kinase inhibitors (TKIs) (Proffered paper session 1: NSCLC, metastatic).
4
Final analysis results from the Phase 3 LITESPARK-011 study evaluating WELIREG
®
(belzutifan), Merck’s first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, in combination with LENVIMA
®
(lenvatinib), an orally available multiple receptor TKI discovered by Eisai, for patients with advanced renal cell carcinoma with a clear cell component following a PD-1 or PD-L1 inhibitor (Presentation #3587O, Proffered paper session 2: Genitourinary tumours, renal and urothelial).
5
Merck investor event
Merck will hold an Oncology Investor Event to coincide with the ESMO 2026 Congress on Monday, October 26, 7:30 p.m. CET/2:30 p.m. ET, during which senior management will provide an update on the company’s oncology strategy and program. The event will take place in Madrid, Spain, and will be accessible via webcast. Investors, analysts, members of the media and the general public are invited to listen to a webcast of the presentation via this
weblink
. All participants may join the call by dialing (800) 369-2154 (U.S. and Canada Toll-Free) or (517) 308-9422 and using the access code 8984239.
Details on presentations listed above and additional key presentations for Merck
Breast cancer
Final OS analysis of sacituzumab tirumotecan versus chemotherapy in previously treated locally recurrent or metastatic triple-negative breast cancer: Phase III OptiTROP-Breast01. M. Li.
4
Presentation #4639RO, Rapid oral session 2: Breast cancer, advanced stage
Results from KEYNOTE-B49: A Phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC). H. S. Rugo.
Presentation #LBA51, Proffered paper session 2: Breast cancer, early and advanced stage
Association between disease control and patient-reported functioning and quality of life in the ASCENT-04/KEYNOTE-D19 study. K. Kalinsky.
6
Presentation #4659P, Poster session: Triple negative breast cancer
Gastrointestinal cancers
Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: Results from a Phase I study. D. J. Pinato.
1
Presentation #3151P, Poster session: Pancreatic cancer
Genitourinary cancers
Final analysis of the Phase 3 LITESPARK-011 study: Belzutifan (bel) plus lenvatinib (len) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy. D. Y. Heng.
5
Presentation #3587O, Proffered paper session 2: Genitourinary tumours, renal and urothelial
Final protocol-prespecified analysis of the Phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab versus placebo in clear cell renal cell carcinoma (ccRCC). T. K. Choueiri.
Presentation #3589RO, Rapid oral session 2: Genitourinary tumours, renal and urothelial
Enfortumab vedotin (EV) with or without pembrolizumab (P) as first-line (1L) treatment for cisplatin (cis)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term follow-up analysis from EV-103 cohorts DE/A and K. J. P. Maroto Rey.
7
Presentation #4740RO, Rapid oral session 1: Genitourinary tumours, renal and urothelial
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin. J. A. Chatzkel.
7
Presentation #4734O, Proffered paper session 1: Genitourinary tumour, renal and urothelial
Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the Phase 3 KEYNOTE-B15 study. A. Gomez de Liano Lista.
7
Presentation #4738RO, Rapid oral session 1: Genitourinary tumours, renal and urothelial
Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: Ad hoc analysis from KEYNOTE-905. A. Ullén.
7
Presentation #4733O, Proffered paper session 1: Genitourinary tumour, renal and urothelial
Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) for locally advanced or metastatic urothelial carcinoma (la/mUC): Results from a Phase 2 Study (2870-002/SKB264-II-06). X. Bian.
4
Presentation #4739RO, Rapid oral session 1: Genitourinary tumours, renal and urothelial
Updated results from the Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC). G. von Amsberg.
Presentation #2217RO, Rapid oral session: Genitourinary tumours, prostate, penile and testis
Gynecologic cancers
Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the Phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study. D. Lorusso.
2,3
Presentation #LBA11, Proffered paper session: Presidential Symposium III
KEYNOTE-C93/GOG-3064/ENGOT-en15: Phase 3, randomized, open-label study of first-line (1L) pembrolizumab (pembro) vs carboplatin (C) + paclitaxel (P) in mismatch repair-deficient (dMMR) advanced or recurrent endometrial carcinoma (a/rEC). B. M. Slomovitz.
3
Presentation #LBA12, Proffered paper session: Presidential Symposium III
Raludotatug deruxtecan (R-DXd) + bevacizumab (bev) in participants (pts) with platinum-resistant recurrent ovarian cancer (PROC): Results for cohort B-1 of the Phase 1b/2 REJOICE-Ovarian02 study. A. Oaknin.
8
Presentation #1247RO, Rapid oral session 2: Gynaecological cancers
Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): An updated analysis of efficacy and tolerability from the Ph 2 part of REJOICE-Ovarian01. K. Hasegawa.
8
Presentation #1331P, Poster session: Gynaecological cancers
NRG-GY020: Phase III randomized trial of radiation +/- MK-3475 (pembrolizumab) for newly diagnosed early-stage high intermediate risk (HIR) mismatch repair deficient (dMMR) endometrioid endometrial cancer. F. Backes.
9
Presentation #1239O, Proffered paper session: Gynaecological cancers
Sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC): Results from a Phase 2 study (2870-002/SKB264-II-06). L. Chen.
4
Presentation #1259P, Poster session: Gynaecological cancers
Head and neck cancer
Practical considerations for adopting perioperative pembrolizumab in locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Europe: Insights from KEYNOTE-689. M. Oliva.
Presentation #1580P, Poster session: Head and neck cancer, excluding thyroid
Lung cancer
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus chemotherapy (chemo) plus pembrolizumab (P) as first-line (1L) treatment for PD-L1 negative advanced non-squamous (nsq) NSCLC: Randomized Phase 3 OptiTROP-Lung06 study. C. Zhou.
4
Presentation #LBA66, Proffered paper session 1: NSCLC, metastatic
Final OS analysis of sacituzumab tirumotecan (sac-TMT) versus platinum-based chemotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) after progression on EGFR-TKI: Phase III OptiTROP-Lung04 study. W.F. Fang.
4
Presentation #LBA67, Proffered paper session 1: NSCLC, metastatic
Calderasib (MK-1084), alone or in combination, for KRAS G12C-mutant metastatic non-small cell lung cancer (mNSCLC). M. A. N. Sendur.
10
Presentation #2680RO, Rapid oral session 2: NSCLC, metastatic
Final analysis of adjuvant pembrolizumab (pembro) in resected early-stage non–small-cell lung cancer (NSCLC): Phase 3 PEARLS/KEYNOTE-091 study. M. E. O’Brien.
Presentation #2511O, Proffered paper session: Non-metastatic NSCLC and other thoracic malignancies
Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): IDeate-Lung01 updated results. M. Ahn.
8
Presentation #3842P, Poster session: SCLC
Melanoma
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL). G. V. Long.
1
Presentation #LBA1, Proffered paper session: Presidential Symposium I
STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini) and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma. D. Schadendorf.
7
Presentation #2071O, Proffered paper session: Melanoma and other skin tumours
Physician perspectives on defining cure in early-stage melanoma. H. M. Shaw.
Presentation #2173eP, ePoster session: Melanoma
Patritumab deruxtecan (HER3-DXd) in melanoma after anti-PD-(L)1 therapy: Primary analysis from HERTHENA-PanTumor01. M. McKean.
8
Presentation #2073RO, Rapid oral session: Melanoma and other skin tumours
Multi-tumor
Final results of the TUXEDO-3 Phase II trial of patritumab deruxtecan (HER3-DXd) in active brain metastases (BMs) and leptomeningeal disease (LMD). M. Preusser.
8
Presentation #690O, Proffered paper session: CNS tumours
Calderasib monotherapy in various KRAS G12C-mutated advanced solid tumors: Results from the Phase 1 KANDLELIT-001 study. M Kwiatkowski.
10
Presentation #1039P, Poster session: Developmental therapeutics
1
In collaboration with Moderna
2
In collaboration with Kelun-Biotech
3
In collaboration with the European Network for Gynaecological Oncology Trial (ENGOT) groups and the GOG Foundation, Inc. (GOG)
4
Led by Kelun-Biotech, conducted in China
5
In collaboration with Eisai
6
In collaboration with Gilead
7
In collaboration with Astellas/Pfizer
8
In collaboration with Daiichi Sankyo
9
Sponsored by U.S. National Cancer Institute (NCI)/led by NRG Oncology
10
In collaboration with Taiho Pharmaceutical Co. Ltd and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd
About intismeran autogene
Intismeran autogene (intismeran; V940 or mRNA-4157) is a novel, potential first-in-class investigational messenger RNA (mRNA)-based individualized neoantigen therapy (INT) jointly developed by Merck and Moderna. Intismeran is designed and produced using a patient's tumor sample to identify the unique mutational signature, or "fingerprint," of their cancer and generate an anti-tumor immune response. Each therapy consists of a synthetic mRNA coding for up to 34 neoantigens and is tailored to the unique biology of an individual patient's tumor. Upon administration, the RNA-encoded neoantigen sequences are translated in the body and presented to the immune system, a key step in generating specific T-cell responses against cancer cells. Individualized neoantigen therapies are designed to train and activate an anti-tumor immune response based on the unique mutational signature of a patient's tumor. Merck and Moderna are advancing the robust
INTerpath clinical development program
evaluating the safety and efficacy of intismeran in combination with KEYTRUDA and other anti-cancer therapies, and as a monotherapy.
About sacituzumab tirumotecan (sac-TMT)
Sac-TMT is an investigational TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a unique bifunctional linker designed with the potential to maximize payload delivery to tumor cells and minimize payload loss while circulating in the body.
TROP2 is overexpressed on tumor cells compared to healthy cells in many common cancers, and through the TroFuse clinical development program, Merck is evaluating sac-TMT in 18 ongoing global Phase 3 trials across multiple tumor types, the broadest range of disease and treatment settings compared to any TROP2-directed ADC to date. The
TroFuse development program
spans early-to-late-stage disease in more than nine disease areas and includes more than 15,000 patients worldwide. Numerous Phase 3 trials are exploring sac-TMT as monotherapy and in combination with immunotherapies, aiming to improve survival and quality of life for patients with advanced and earlier-stage cancers.
About calderasib
Calderasib (MK-1084) is an investigational, highly potent and specific next-generation
KRAS
G12C covalent inhibitor. Mutations in
KRAS
are among the most prevalent mutations found in cancer, occurring with high frequency in non-small cell lung cancer (NSCLC), pancreatic, urogenital and colorectal cancers. The
KRAS
G12C mutation is the most frequently observed
KRAS
mutation in patients, occurring in approximately 14% of patients with NSCLC (adenocarcinoma). Despite decades of research and recognition of the therapeutic importance of targeting
KRAS
, the development of small molecule inhibitors targeting
KRAS
mutations has been challenging.
About KEYTRUDA
®
(pembrolizumab) injection for intravenous use, 100 mg
KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
Merck has the industry’s largest immuno-oncology clinical research program. There are currently more than 2,800 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.
Selected Indications in the U.S. for KEYTRUDA
®
(pembrolizumab)
Melanoma
KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.
Non-Small Cell Lung Cancer
KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-authorized test, with no EGFR or ALK genomic tumor aberrations, and is:
Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
metastatic.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-authorized test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.
KEYTRUDA is indicated for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
KEYTRUDA, as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.
Head and Neck Squamous Cell Cancer
KEYTRUDA is indicated for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-authorized test.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
Urothelial Cancer
KEYTRUDA, in combination with enfortumab vedotin-ejfv, is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer.
KEYTRUDA, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma:
who are not eligible for any platinum-containing chemotherapy, or
who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
KEYTRUDA, in combination with enfortumab vedotin-ejfv, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with muscle invasive bladder cancer (MIBC).
KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
Renal Cell Carcinoma
KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of adult patients with advanced RCC.
KEYTRUDA is indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
KEYTRUDA, in combination with belzutifan, is indicated for the adjuvant treatment of adult patients with RCC with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Endometrial Carcinoma
KEYTRUDA, in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, is indicated for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
KEYTRUDA, as a single agent, is indicated for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
Contacts
Media Contacts:
Julie Cunningham
julie.cunningham@merck.com
Justine Moore
justine.moore@merck.com
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583
Read full story here
Clinical ResultPhase 3Phase 1Phase 2ADC
13 Oct 2026
iStock,
wildpixel
Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.
An open fundraising window, retreating policy pressure and a soaring biotech stock index are bringing a fresh breath of air across the biopharma world as the sector heads into the third quarter earnings reporting period.
Potential deals and launch execution will be the tale of the quarter, analysts have declared. In terms of M&A, the industry has already exceeded 2025’s tally of $136 billion across 57 deals, Truist Securities wrote at the end of September. Many potential takeout targets have undergone a re-rating, which means rising valuations could stir up dealmaking behind the scenes.
“We note the sector’s cheap optionality—the names trading below cash, and the outsized takeout premiums that defined 2025—has largely been priced out, which to us reflects re-rated targets and not cheaper assets,” Truist Securities wrote last week.
Mergers & acquisitions
M&A slows in Q3 but Vertex snags one of the year’s biggest in $10B Crinetics buy
After a frantic second quarter, M&A steadied with just under $30 billion across 22 total transactions, according to a
BioSpace
analysis.
October 1, 2026
·
1 min read
Read more
Therefore, pharma CEOs in particular should expect business development expectations for the final quarter of this year to dominate the conversation for this Q3 earnings season. Buyers will increasingly be looking to validated biotech targets with near-term data readouts plus differentiated pro Truist said.
As always, Johnson & Johnson will kick off the earnings period, with a conference call scheduled for Tuesday, Oct. 13 at 8:30 a.m. ET. Here, we look ahead to a handful of company announcements that analysts will be watching carefully.
How is RevMed’s Rasonque launch going?
Truist is watching a few names closely heading into the fourth quarter. Top of the list is Revolution Medicines, which will likely be able to claim the biggest success story of 2026. The company’s pancreatic cancer medicine finally broke through the intractable disease, swiftly earning an
FDA greenlight
after
doubling survival
in a Phase 3 trial.
Now, RevMed will be reporting initial launch numbers for the therapy. Truist expects the Q3 report to include about $14 million in initial sales for the drug, now known as Rasonque. This falls just short of the consensus estimate of $20 million. Nevertheless, the launch has so far been heralded a success by analysts, including Truist.
If the trajectory continues, RevMed, with its first approved medicine, could be on the way to $100 million or more in sales for this year, according to Truist.
Key opinion leaders have been bullish on the therapy, informing Truist that all available patients with pancreatic ductal adenocarcinoma are getting access to treatment with no payer pushback. The firm therefore boosted expectations for 2026 from $102 million to $113 million. Back in September, Truist projected $13.8 billion in peak revenue for Rasonque.
But RevMed has been vague with what it has shared about the new drug, Truist pointed out. “Management is understandably more guarded on where the launch stands, has not indicated which metrics it will share and continues to characterize demand as healthy.”
Investors, therefore, will be eagerly listening for any details on RevMed’s upcoming earnings call.
Cancer
RevMed could become ‘next oncology titan’ with Rasonque nod
A future expansion of Rasonque into first-line pancreatic ductal adenocarcinoma could set Revolution Medicines up to hit $2.3 billion in sales by 2028, according to Truist Securities.
August 27, 2026
·
2 min read
·
Tristan Manalac
Read more
Jazz aims big with GEA label expansion
Jazz Pharmaceuticals is “firing on all cylinders” thanks to Ziihera, which in August added a new indication for unresectable or metastatic HER2+ advanced gastroesophageal adenocarcinoma (GEA). Truist anticipates topline earnings for the quarter of $1.22 billion, just above consensus of about $1.21 billion.
The company is expected to take an $800 million in-process R&D charge related to the $1.3 billion acquisition of
Actio Biosciences
from August.
Ziihera, which was already cleared for a certain type of biliary track cancer, is expected to reach peak sales of between $3–5 billion, according to executives. This value rose from a $2 billion peak after the GEA approval.
Truist and investors will be looking for information on the early launch dynamics and how Jazz expects to reach a predicted 8,000 U.S. patients despite just 3,000–4,000 having confirmed HER2+ disease validated by testing.
Attendees to the Q3 call will also be keenly listening for any further deal talks after the Actio takeout.
Approvals
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
August 26, 2026
·
2 min read
·
Tristan Manalac
Read more
Ultragenyx: A tale of two launches
Ultragenyx also has some exciting launch news to share after snagging FDA approvals earlier this year for the rare disease gene therapies
Fayuvi
and
Genglycos
, William Blair noted.
The company heads into the reporting period having sold a priority review voucher (PRV) for a cool $210 million thanks to a hot market for the regulatory fast passes. Ultragenyx earned a PRV each for Fayuvi and Genglycos, meaning the biotech still holds one. Executives plan to hold onto it for now and sell in the future.
Elsewhere, Ultragenyx is currently executing an expense reduction plan that aims to help the biotech achieve profitability in 2027.
Rare diseases
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat
The recent FDA approval of Fayuvi for a rare, childhood neurodegenerative disease was “particularly special” for Ultragenyx CEO Emil Kakkis. It could also, along with an August nod for another gene therapy, help offset recent challenges brought on by two asset failures.
September 28, 2026
·
5 min read
·
Heather McKenzie
Read more
Others to watch
Merck will report on sales figures for rising products Winrevair and Keytruda Qlex, Guggenheim said last week. But investors will really be watching for scraps of news for the pharma’s major clinical quarter to come. Merck will report full data for two upcoming oncology assets at the European Society for Medical Oncology Congress in Madrid, Spain between October 23-27: its Moderna-partnered personalized mRNA-based cancer vaccine intismeran autogene and an investigational antibody-drug conjugate (ADC) called sac-TMT that the pharma licensed from Kelun-Biotech. Besides the earnings call on October 29, Merck will host an investor call alongside the ESMO conference on Oct 26.
cancer
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
August 20, 2026
·
2 min read
·
Annalee Armstrong
Read more
Other companies for which business development will be key topics include Regeneron, Amgen and J&J, according to analysts.
VaccineDrug ApprovalAcquisitionPhase 3
100 Deals associated with Sacituzumab tirumotecan
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | China | 02 Feb 2026 | |
| EGFR-mutated non-small Cell Lung Cancer | China | 30 Sep 2025 | |
| EGFR positive Non-squamous non-small cell lung cancer | China | 04 Mar 2025 | |
| Advanced Triple-Negative Breast Carcinoma | China | 22 Nov 2024 | |
| Metastatic Triple-Negative Breast Carcinoma | China | 22 Nov 2024 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Triple-Negative Breast Carcinoma | NDA/BLA | China | 30 Jul 2026 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | NDA/BLA | China | 09 May 2026 | |
| metastatic non-small cell lung cancer | NDA/BLA | China | 09 May 2026 | |
| PD-L1 positive Non-Small Cell Lung Cancer | NDA/BLA | China | 09 May 2026 | |
| Triple Negative Breast Cancer | NDA/BLA | China | 11 Dec 2023 | |
| Muscle Invasive Bladder Carcinoma | Phase 3 | - | 20 Oct 2026 | |
| Bladder Cancer | Phase 3 | United States | 23 Apr 2026 | |
| Bladder Cancer | Phase 3 | United States | 23 Apr 2026 | |
| Bladder Cancer | Phase 3 | China | 23 Apr 2026 | |
| Bladder Cancer | Phase 3 | Japan | 23 Apr 2026 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
| Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
|---|
Phase 3 | 263 | byvracjlmj(vtmlgvyvuu) = cotvbjpzaq msfhzzjmag (akosijuuwl ) View more | Positive | 23 Oct 2026 | |||
Chemotherapy | byvracjlmj(vtmlgvyvuu) = wxqgwfoqef msfhzzjmag (akosijuuwl ) View more | ||||||
Phase 2 | Metastatic urothelial carcinoma TROP2 | PD-L1 | 40 | fzgitlvljs(riqgqbkult) = olngxouizj huqutgtplw (qmxbrpisel, 51 - 81) View more | Positive | 23 Oct 2026 | ||
fzgitlvljs(riqgqbkult) = gfbcivejec huqutgtplw (qmxbrpisel, 47 - 90) | |||||||
Phase 1/2 | 50 | hxqpkxthye(vxgvsrjacx) = wleytedsyf teculaqmxl (jumylqttut ) View more | Positive | 23 Oct 2026 | |||
Phase 1/2 | 158 | znzspydvig(ezjyipkfcj) = sdqnfychab ezobagcviw (mozsxadrer ) View more | Positive | 01 Oct 2026 | |||
znzspydvig(ezjyipkfcj) = tpkxgiyuge ezobagcviw (mozsxadrer ) View more | |||||||
Phase 3 | 1,015 | tjdoccrtcv(cblksyliya) = dditvfnwfp xwxeynenuq (pawpwngrve ) View more | Positive | 01 Oct 2026 | |||
tjdoccrtcv(cblksyliya) = sgcziujzqe xwxeynenuq (pawpwngrve ) View more | |||||||
Phase 2 | EGFR G719X | S768I | L861Q ... View more | 90 | alykhtpddr(abbvycecjg) = ealaeviutn jpxauuwclu (qskfyzcyyc ) View more | Positive | 12 Sep 2026 | ||
Phase 3 | 528 | yroxbzakyy(qhbyekebep) = xetzzguemx zsfnedbddk (nftyaxglck ) | Positive | 11 Sep 2026 | |||
Not Applicable | Advanced Lung Non-Small Cell Carcinoma Second line | First line | 65 | Sacituzumab tirumotecan-based therapy | sicbuxhjhi(uvzcehzwip) = kbzqvdhqfp kqdvwnmdtq (aqvpcjknfu ) View more | Positive | 11 Sep 2026 | |
Sacituzumab tirumotecan-based therapy (Sacituzumab tirumotecan as first-line therapy) | nryqywzbov(huydjunvgx) = srqwngldse tnsktzzazv (bqvsdlfzqk ) | ||||||
Phase 2 | Advanced Cervical Carcinoma TROP2 | PD-L1 | 153 | boczvgzrqu(nnyhntalbz) = okmvgutjef yzkcjcsajx (yvdelbwmfq, 25.9 - 41.4) View more | Positive | 11 Sep 2026 | ||
Phase 1/2 | 166 | jiuhuvhkpd(lnmwjzcjii) = mwfprdadnr ltspcaigsd (aujgksthbs, 18.0 - 34.5) View more | Positive | 11 Sep 2026 | |||
jiuhuvhkpd(lnmwjzcjii) = kkxbrkypvv ltspcaigsd (aujgksthbs, 18.3 - 45.4) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free